Thrombosis Research
Volume 126, Issue 3 , Pages 238-242 , September 2010

Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms

  • Jérôme Duchemin

      Affiliations

    • CHU Brest, Laboratoire d'Hématologie, Hôpital La Cavale Blanche, Brest, France
    • ,
  • Valérie Ugo

      Affiliations

    • CHU Brest, Laboratoire d'Hématologie, Hôpital La Cavale Blanche, Brest, France
    • INSERM, U613, Brest, France
    • Université de Brest, UFR Médecine et Sciences de la Santé, Brest, France
    • ,
  • Jean-Christophe Ianotto

      Affiliations

    • CHU Brest, Institut de Cancérologie et d'Hématologie, Hôpital Morvan, Brest, France
    • ,
  • Lydie Lecucq

      Affiliations

    • CHU Brest, Laboratoire d'Hématologie, Hôpital La Cavale Blanche, Brest, France
    • ,
  • Bernard Mercier

      Affiliations

    • INSERM, U613, Brest, France
    • ,
  • Jean-François Abgrall

      Affiliations

    • CHU Brest, Laboratoire d'Hématologie, Hôpital La Cavale Blanche, Brest, France
    • Université de Brest, UFR Médecine et Sciences de la Santé, Brest, France
    • Corresponding Author InformationCorresponding author. Service d'Hématologie biologique, Hôpital La Cavale Blanche, Bd Tanguy Prigent, 29609 Brest Cedex, France. Tel.: +33 2 98 34 70 33; fax: +33 2 98 34 78 39.

Received 19 March 2010 ,Revised 21 June 2010 ,Accepted 29 June 2010.

References 

  1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemai vera. Nature. 2005;434:1144–1148
  2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790
  3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemai vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  5. Bellucci S, Michiels JJ. The role of JAK2 V6\17F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypertensive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:381–398
  6. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19:617–633
  7. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109:2310–2313
  8. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi RM, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–2452
  9. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol. 2006;132:244–245
  10. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–136
  11. Falanga M, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–4266
  12. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157–171
  13. Dignat George F. Microparticles in vascular diseases. Thromb Res. 2008;122:555–559
  14. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res. 2008;123:8–23
  15. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009;101:439–451
  16. Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocytopenia. Haematologica. 2009;94:911–918
  17. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15
  18. Couturaud F, Duchemin J, Leroyer C, Delahousse B, Abgrall JF, Mottier D, et al. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Heamost. 2008;99:223–228
  19. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukaemia transition by treatment. Semin Hematol. 1997;34:29–39
  20. Campbell PJ, Scott LM, Baxter EJ, Bench AJ, Green AR, Erber WN. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med. 2006;125:253–264
  21. Leroyer C, Mercier B, Escoffre M, Férec C, Mottier D. Factor V Leiden prevalence in venous thromboembolism patients. Chest. 1997;111:1603–1606
  22. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochem Biophys Acta. 1983;736:57–66
  23. Mayer LD, Hope MJ, Cullis PR. Vesicles of variables sizes produced by a rapid extrusion procedure. Biochem Biophys Acta. 1986;858:161–168
  24. Duchemin J, Pittet JL, Tartary M, Béguin S, Gaussem P, Alhenc-Gelas M, et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost. 1994;71:331–338
  25. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, et al. The significance of shed membrane microparticles during programmed cell death in vitro or in vivo, in HIV infection. J Clin Invest. 1997;99:1546–1554
  26. Marchetti M, Castoldi E, Spronk HMH, van Oerle R, Balducci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocytemia and polycythemia vera. Blood. 2008;112:4061–4068
  27. Tesselaar MET, Rominj FPHTM, van der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticles-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2007;5:520–527
  28. Sarig G, Michaeli Y, Lanir N, Brenner B, Haim N. Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost. 2005;3:589–590
  29. Lawrie AS, Harrison P, Cardigan RA, Mackie IJ. The characterization and impact of microparticles on haemostasis within fresh-frozen plasma. Vox Sang. 2008;95:197–204
  30. Chantarangkul V, Clerici M, Bressi C, Giesen PLA, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica. 2003;88:547–554
  31. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84:102–108
  32. Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography±thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost. 2006;96:562–567
  33. Lawrie AS, Albanyan A, Cardigan RA, Mackie IJ, Harrison P. Microparticle sizing by dynamic light scattering in fresh-frozen plasma. Vox Sang. 2009;96:206–212

☆ The authors certify that they have no affiliation with or financial involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript (e.g., employment, consultancies, stock ownership or honoraria).

PII: S0049-3848(10)00365-8

doi: 10.1016/j.thromres.2010.06.025

Thrombosis Research
Volume 126, Issue 3 , Pages 238-242 , September 2010

Article Tools